In what appears to be the first case to consider the issue, an Eastern District of Missouri court recently rejected the argument that the Supreme Court’s Loper Bright Enterprises v. Raimondo decision overruling Chevron deference undermines the basis for express preemption in medical device cases.

On July 18, 2025, President Donald Trump signed into law the Guiding and Establishing National Innovation for U.S. Stablecoins Act of 2025 (the GENIUS Act or the Act), following its bipartisan passage by the Senate on June 17 (68–30) and the House on July 17 (308–122). 

The Central District of California recently shut down, on preemption grounds, a group of class-action plaintiffs’ second attempt to assert claims alleging that benzoyl peroxide (BPO) in over-the-counter (OTC) acne treatments unavoidably degrades into the carcinogen benzene.